

ACELRX PHARMACEUTICALS INC
Form 8-K
May 06, 2015
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2015

ACELRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 001-35068 41-2193603
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)

351 Galveston Drive

Redwood City, CA 94063

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (650) 216-3500

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other
Events.**

On May 4, 2015, AcclRx Pharmaceuticals, Inc., or the Company, conducted a conference call during which members of its senior management team discussed a regulatory update for Zalviso, other program updates, financial results for the quarter ended March 31, 2015 and certain other information. A copy of the transcript of the conference call is attached as Exhibit 99.1 to this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Description

Number

99.1	Transcript of AcclRx Pharmaceuticals, Inc. Quarter Ended March 31, 2015 Earnings Conference Call on May 4, 2015, at 4:30 p.m. ET.
------	---

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ACELRX PHARMACEUTICALS,
May INC.
6,
2015

By: /s/ Jane
 Wright-Mitchell
 Jane
 Wright-Mitchell

 Chief Financial
 Officer